About this Research Topic
The field of tissue engineering and regenerative (TERM) has shown that it is possible to generate and study various types of tissue replicas in vitro. However, most of the processes employed within TERM tend to be highly labor-intensive and therefore economically impracticable in a large-scale context. Furthermore, and due to the extreme complexity normally found in native and diseased tissues and organs, it becomes difficult to mimic their fine anatomies, dynamic physiologies and environments in high detail and in real time.
Process automation may be the most logical way to mass produce such highly detailed and realistic tissue replicas in an economic and timely manner. Technologies such as additive manufacturing, bioreactors and organs-on-chips have been the driving forces behind this automation trend, given that they allow to accurately and consistently build cell-biomaterial constructs and further dynamically feed, stimulate, steer and analyze their development in native-like or disease-like conditions.
The goal of this Research Topic is to focus on novel developments related with the overall automation of tissue engineering and regenerative medicine strategies, employing technologies such as additive manufacturing, bioreactors and organs-on-chips. This Research Topic intends to showcase the current state-of-the-art of automation in TERM as well as demonstrating the present and future potential impact of automation in medicine and healthcare.
Both Review and Original Research articles to be included in this Research Topic are expected to be related with the following areas:
• Biofabrication
• Organs-on-chips
• Automation in tissue engineering and regenerative medicine
• Tissue and/or organ models
Dr. Pedro Costa is founder, CEO/CTO and shareholder of the company Biofabics Lda. Dr. Dietmar Hutmacher is founder and shareholder of the companies Osteopore International Pte Ltd, Gelomics Pty Ltd, BellaSeno GmbH and Polvax Pty Ltd. All other Topic Editors declare no other conflicts of interest in relation to the subject of this Research Topic.
Process automation may be the most logical way to mass produce such highly detailed and realistic tissue replicas in an economic and timely manner. Technologies such as additive manufacturing, bioreactors and organs-on-chips have been the driving forces behind this automation trend, given that they allow to accurately and consistently build cell-biomaterial constructs and further dynamically feed, stimulate, steer and analyze their development in native-like or disease-like conditions.
The goal of this Research Topic is to focus on novel developments related with the overall automation of tissue engineering and regenerative medicine strategies, employing technologies such as additive manufacturing, bioreactors and organs-on-chips. This Research Topic intends to showcase the current state-of-the-art of automation in TERM as well as demonstrating the present and future potential impact of automation in medicine and healthcare.
Both Review and Original Research articles to be included in this Research Topic are expected to be related with the following areas:
• Biofabrication
• Organs-on-chips
• Automation in tissue engineering and regenerative medicine
• Tissue and/or organ models
Dr. Pedro Costa is founder, CEO/CTO and shareholder of the company Biofabics Lda. Dr. Dietmar Hutmacher is founder and shareholder of the companies Osteopore International Pte Ltd, Gelomics Pty Ltd, BellaSeno GmbH and Polvax Pty Ltd. All other Topic Editors declare no other conflicts of interest in relation to the subject of this Research Topic.
Keywords: Biofabrication, Organs-on-Chips, Bioreactors, Automation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
